HIV disease metrics and COVID‐19 infection severity and outcomes in people living with HIV in central and eastern Europe

Abstract

AbstractBackgroundTo date there remains much ambiguity in the literature regarding the immunological interplay between SARS‐CoV‐2 and HIV and the true risk posed to coinfected individuals. There has been little conclusive data regarding the use of CD4 cell count and HIV viral load stratification as predictors of COVID‐19 severity in this cohort.MethodsWe performed a retrospective, observational cohort study on people living with HIV (PLWH) who contracted COVID‐19 in central and eastern Europe. We enrolled 536 patients from 16 countries using an online survey. We evaluated patient demographics, HIV characteristics and COVID‐19 presentation and outcomes. Statistical analysis was performed using SPSS 20.1.ResultsThe majority of the study cohort were male (76.4%) and 152 (28.3%) had a significant medical comorbidity. Median CD4 cell count at COVID‐19 diagnosis was 605 cells/μL [interquartile range (IQR) 409–824]. The majority of patients on antiretroviral therapy (ART) were virally suppressed (92%). In univariate analysis, CD4 cell count <350 cells/μL was associated with higher rates of hospitalization (p < 0.0001) and respiratory failure (p < 0.0001). Univariate and multivariate analyses found that an undetectable HIV VL was associated with a lower rate of hospitalization (p < 0.0001), respiratory failure (p < 0.0001), ICU admission or death (p < 0.0001), and with a higher chance of full recovery (p < 0.0001).ConclusionWe can conclude that detectable HIV viral load was an independent risk factor for severe COVID‐19 illness and can be used as a prognostic indicator in this cohort.